Next-Generation Tissue Kallikrein 1 Delivery Systems for Personalized Ischemic Condition Treatment

The present inventive concept envisions a paradigm shift in tissue kallikrein 1 delivery systems, leveraging advancements in wearable technology, machine learning, and sustained-release formulations to provide personalized, real-time treatment of ischemic conditions.

The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions, but had limitations in terms of dosing regimens, patient variability, and lack of real-time monitoring. The present inventive concept addresses these limitations by introducing wearable devices, machine learning algorithms, and sustained-release formulations to provide more effective and personalized treatment options.

The new inventive concept comprises a wearable device with a transdermal patch containing a dosage form of tissue kallikrein 1, which is configured to monitor the subject's vital signs and adjust the dosage form delivery in real-time based on the monitored vital signs. Additionally, a machine learning algorithm is used to predict optimal dosage forms and delivery schedules for individual subjects, utilizing genomic data and medical history to generate a customized treatment plan. Furthermore, a sustained-release dosage form of tissue kallikrein 1 is designed to maintain a therapeutically-effective serum level for at least 7 days after a single administration, reducing the need for frequent dosing. A device for transdermal delivery of tissue kallikrein 1, comprising a micro-needle array and a reservoir containing the dosage form, is also disclosed. Finally, a system for remote monitoring and management of ischemic conditions, comprising a mobile application that receives data from the wearable device and transmits alerts and treatment recommendations to healthcare providers and caregivers, is envisioned.

The new claims introduce a wearable device with real-time monitoring and adjustment capabilities, machine learning algorithms for personalized treatment, and sustained-release formulations, which are not present in the original patent. These features provide a significant improvement over the original patent, enabling more effective and personalized treatment of ischemic conditions.

Alternative embodiments of the inventive concept could include different wearable device designs, varying machine learning algorithms, and diverse sustained-release formulations. Additionally, the inventive concept could be adapted for use in other therapeutic areas, such as cancer treatment or inflammatory disorders.

The present inventive concept has significant commercial potential in the pharmaceutical and medical device industries, with potential applications in ischemic condition treatment, personalized medicine, and remote patient monitoring. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve treatment outcomes and reduce healthcare costs.